The influence of Simvastatin and Korargin on the clinical course of coronary heart disease, body weight and distribution of adipose tissue in patients with type 2 diabetes mellitus.

• Main Author: E. A. Pogrebniak
• Format: Article
• Language: English
• Published: Zaporozhye State Medical University 2013-06-01
• Series: Zaporožskij Medicinskij Žurnal
• Subjects: coronary heart disease; diabetes; simvastatin; korargin
• Online Access: http://zmj.zsmu.edu.ua/article/view/13574/11933

Diabetes mellitus (DM) is one of the most influential risk factors for the development of cardiovascular diseases. Incidence of coronary heart diseases (CHD) and acute myocardial infarction in diabetic patients is much higher than in people without diabetes. Type 2 DM affects other risk factors of CHD due to the fact that, as a rule, it is accompanied by obesity, hypertension, hypertriglyceridemia and decrease of high density lipoproteins. Purpose of the investigation – to improve the efficiency of treatment of patients with CHD with type 2 DM based on the effect of Simvastatin and Korargin on it’s clinical course, body weight and the distribution of adipose tissue. Materials and methods of the investigation. The study involved 175 patients with CHD aged from 34 to 87, mean age was 61,0 ± 8,0 years, among whom there were 96 (54,9%) men and 79 (45,1%) women. All surveyed received conventional treatment. Depending on supplementary prescriptions patients were divided into eight groups: 1 group - 22 patients with CHD who were prescribed Simvastatin, 2 group - 20 patients with CHD who were prescribed Korargin, 3 group - 20 patients with coronary artery disease who were prescribed simultaneously both Simvastatin and Korarhin, 4 group - 20 patients with CHD with type 2 diabetes treated with Simvastatin, 5 group - 23 patients with CHD with type 2 diabetes who took Korargin, 6 group - 27 patients with CHD with type 2 diabetes, who were prescribed both Simvastatin and Korargin in addition to conventional treatments, 7 group - 20 patients with CHD who received only conventional treatments, 8 group - 23 patients with coronary artery disease combined with type 2 diabetes who received only conventional treatments. Simvastatin ("Vazostat-Health" FC "Health", Kharkiv) was administered at a daily dose of 20 mg at night during 6 months, Korargin (JSC "Engineer", Uman) - 0,1 g of L-arginine hydrochloride with 0.1 g of inosine – was administered at a dose of 3 tablets twice per daily before meals for 2 months. Findings of the investigation and discussion. The most prominent clinical effect on major clinical indicators of CHD (the average number of angina attacks per day, the average duration of angina attacks and nitroglycerin daily dose) in CHD patients with type 2 DM was provided with the combination of Simvastatin and Korargin on the background of the conventional treatments, due to the combined action of two drugs with different mechanisms of actions synergistically improving endothelial function. The body weight and distribution of adipose tissue in patients with CHD with type 2 DM (waist size, hip size, and WS/HS) were significantly more pronounced on the background of treatment with Simvastatin combined with Korargin. Conclusion: The supplement of Simvastatin and Korragin to the conventional treatment of patients with CHD with type 2 DM increases effort tolerance. Changes of body weight and distribution of adipose tissue in these patients are significantly more prominent on the background of Simvastatin and Korargin intake.